Investigational drug · Phase 2
NNC0194-0499
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alcohol-related Liver Disease, Non-alcoholic Steatohepatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
11
Any phase or sponsor naming "NNC0194-0499"
First trial start
2021
Aug 31, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NNC0194-0499", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alcohol-related Liver Disease
- Non-alcoholic Steatohepatitis
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "NNC0194-0499" as an intervention, largest first.
- Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05016882 · 698 participants · Start Aug 31, 2021 · Primary completion Dec 17, 2024
Drug: NNC0194 0499 50 mg/mL; Placebo (NNC0194-0499) and 4 more · For: Non-alcoholic Steatohepatitis
Sites: Huntsville, Alabama; Chandler, Arizona; Peoria, Arizona · 255 sites in all
- Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseasePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06409130 · 270 participants · Start May 20, 2024 · Primary completion Nov 21, 2025
Drug: NNC0194-0499; Semaglutide and 6 more · For: Alcohol-related Liver Disease
Sites: Chandler, Arizona; Tucson, Arizona; Lancaster, California · 102 sites in all
- A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 DiabetesActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07087795 · 96 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 12, 2026
Drug: NNC0194-0499; Placebo and 1 more · For: Diabetes Mellitus, Type 1
Sites: Neuss, Germany
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03479892 · 57 participants · Start Mar 13, 2018 · Primary completion Jun 4, 2019
Drug: NNC0194-0499; Placebo · For: Metabolism and Nutrition Disorder; Obesity
Sites: San Antonio, Texas
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03015207 · 56 participants · Start Jan 6, 2017 · Primary completion Oct 26, 2017
Drug: NNC0194-0499; Placebo · For: Metabolism and Nutrition Disorder; Obesity
Sites: San Antonio, Texas
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05766709 · 53 participants · Start Mar 2, 2023 · Primary completion Jan 5, 2024
Drug: NNC0194-0499; Semaglutide and 2 more · For: Non-alcoholic Steatohepatitis
Sites: Montreal, Canada
- A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian MenCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04722653 · 42 participants · Start Feb 2, 2021 · Primary completion Apr 27, 2021
Drug: NNC0194-0499; Placebo (NNC0194-0499 ) · For: Non-alcoholic Steatohepatitis
Sites: Tokyo, Japan
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05727644 · 42 participants · Start Feb 15, 2023 · Primary completion Nov 10, 2023
Drug: NNC0194-0499 · For: Non-alcoholic Steatohepatitis (NASH)
Sites: Berlin, Germany
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06188026 · 34 participants · Start Dec 18, 2023 · Primary completion Dec 30, 2024
Drug: NNC0194-0499; ethinylestradiol/levonorgestrel · For: Healthy Volunteers (Non-alcoholic Steatohepatitis)
Sites: Graz, Austria
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05917938 · 33 participants · Start Jul 4, 2023 · Primary completion Dec 16, 2024
Drug: NNC0194-0499 · For: Hepatic Impairment; Healthy Volunteers
Sites: München, Germany; Gdansk, Poland; Krakow, Poland · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog.
Sass-Ørum K, Tagmose TM, Olsen J, et al. · J Med Chem 2024
Also in development for Alcohol-related Liver Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.